The World Health Organization (WHO) granted approval for Indian drugmaker Bharat Biotech’s home-grown Covid-19 vaccine for emergency use listing, paving the way for Covaxin to be accepted as a valid vaccine in many poor countries.
Two Indian drugmakers requested permission to end their late-stage trials on Merck & Co.’s experimental antiviral drug molnupiravir in moderate Covid-19 patients.
Worldwide deaths related to Covid-19 surpassed 5 million on Oct. 1, according to a Reuters tally, with unvaccinated people particularly exposed to the virulent Delta strain.
A study of 614 fully vaccinated health workers in India found a “significant” drop in their Covid-fighting antibodies within four months of the first shot.
An outbreak of dengue fever is suspected of killing dozens of people in India’s northern state of Uttar Pradesh since the start of September, and authorities launched a campaign to destroy mosquito breeding grounds.
Bharat Biotech’s intranasal Covid-19 vaccine candidate is expected to enter the Phase II portion of a Phase II/III study within the next few weeks. BBV154 marks the second vaccine against the novel coronavirus developed by the India-based company.
Indian drug developer Hetero received emergency use approval from the country’s health authorities to make a generic version of Roche Holding AG’s Covid-19 drug.
India’s drug regulator granted emergency use approval for Zydus Cadila’s Covid-19 vaccine, the world’s first DNA shot against the coronavirus, in adults and children aged 12 years and older.
Bharat Biotech’s a two-dose, injectable Covid-19 vaccine Covaxin is authorized in India for ages 12 and up. The company is moving forward with a second vaccine against the novel coronavirus with a different mode of administration.
Indian vaccine maker Bharat Biotech’s nasal Covid-19 vaccine candidate received regulatory approval for mid-stage to late-stage trials, the government’s ministry of science and technology said in a statement on Aug. 13.
